key: cord-0901229-fcr5fnx4
authors: Wang, Daojiong; Ge, Yushu; Zhong, Bin; Liu, Dan
title: Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: implications for advanced antibody design
date: 2021-03-23
journal: Comput Struct Biotechnol J
DOI: 10.1016/j.csbj.2021.03.021
sha: 6912c67f1f0f72319fe7832ec9252675ba1daade
doc_id: 901229
cord_uid: fcr5fnx4

Neutralizing antibody targeting to the SARS-CoV-2 could provide powerful therapies. A neutralizing antibody CC12.1 which was found in SARS-CoV-2 patient samples provides potential protection from disease. The aim of molecular dynamics simulations is to identify key epitopes that are crucial to the antibody binding of SARS-CoV-2 spike glycoprotein receptor binding domain (RBD) to promote the development of superior antibodies. Binding modes of the antibody were investigated and compared with RBD bound receptor ACE2. Key epitopes were revealed and a distal motif of RBD (residue numbers 473-488) was demonstrated by analyzing dynamic trajectories. Compared to the receptor ACE2, conformation of RBD could be better stabilized through additional interaction of antibody with the distal motif of RBD, which was further found driven by electrostatic complementarity. By further analysis of the extensive hydrogen-bonding networks, residues D405, K417, Y421, Y453, L455, R457, Y473, A475, N487, G502, Y505 of RBD, which mainly interacted with CDR H3/L3 and two conserved motifs SNY, SGGS, were identified as key epitopes. Higher binding free energy calculated after point mutations on key residues confirms the crucial role for the specific binding. Subsequently, mutations of V(H) V98E and V(L) G68D in CC12.1, which could significantly enhance the binding affinity of the antibody, were also proposed. The results indicate the key epitopes for antibody binding and give explanations for failure of neutralization antibody caused by specific residues mutations on structural basis. Simulations of two point mutations on antibody provide feasible information for advanced antibody design.

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which shares around 77.2% amino acid identify with SARS-CoV [1] , have caused much more serious world pandemic [2, 3] . More than one hundred million individuals worldwide were infected, and approximately 2,460,000 death cases were reported by 22 Feb, 2021 [4] . Up to now, there are still few specific antiviral drugs towards to SARS-CoV-2 show the definite effective treatment benefits in clinical trials [5] [6] [7] [8] . Suffice it to say, seeking information used for developing effective therapy against SARS-CoV-2 has become more urgency than ever before. One of the most efficient therapies is using antibody to neutralize virus infectivity [9] , and effective antibodies and vaccines are urgently needed [10, 11] .

Vaccination induces humoral and cellular immune response in immunized individuals and the homologous virus will be neutralized or cleared by neutralizing antibodies (Abs) or specific T cells respectively when it enters an immunized body [12] . Over 200 vaccines are developed, including recombinant protein subunit vaccines, nucleic acid vaccines, viral vector vaccines, inactivated viruses, and live attenuated vaccines [13] . ChAdOx1 nCoV- 19 vaccine , one of the vaccines which entered the phase III clinical trials, shows significant vaccine efficacy of 70·4% after two doses and protection of 64·1% after at least one standard dose, against symptomatic disease [14] . Spike glycoprotein (S) of SARS-CoV-2, which was used for most of COVID-19 vaccines, is capable of activating the immune system through its antigenic parts and the receptor binding domain (RBD) of spike glycoprotein directly interacts with human receptor ACE2 [15, 16] . Whether from patients' serum or synthesis, the neutralizing efficiency of the antibody mainly depends on the binding affinity with the spike glycoprotein RBD of SARS-CoV-2 [17] . Just like SARS-CoV, RBD-binding antibody prevents the recognition by the angiotensin converting enzyme 2 (ACE2) [18] , which takes responsible to the fusion mechanism for cellular entry of the virus [19] [20] [21] [22] . Despite of high similarity of the sequences and overall structures between the RBD of SARS-CoV-2 and SARS-CoV [23] , amino acid mutations cause distinct protein-protein interaction for SARS-CoV-2, which finally lead to various features from molecular to clinical level. First, enhanced receptor binding of SARS-CoV-2 has been determined with more than 10-fold greater binding constant compared to SARS-CoV [24] .

Further study showed how networks of hydrogen-bonding and hydrophobic interactions contribute to the enhanced receptor binding [25] . Subsequently, many SARS-CoV directed antibodies, such as S230, m396 and 80R show no cross-reactivity to SARS-CoV-2 [24, 26] .

Recently separated antibodies responding to SARS-CoV-2 RBD, such as CC12.1 and CC12.3, couldn't neutralize SARS-CoV neither [18] . What mutations contribute to key epitopes causing specific antibody responding? How the potential mutations influence the receptor binding as well as the neutralization efficiency of the antibody? All these questions remain to be answered. In addition, as an RNA virus, the genome of SARS-CoV-2 mutates easily which results in reduced sensitivity to neutralizing antibodies [27, 28] . Without the information about key epitopes for antibody binding, it is frustrated to develop vaccines that can induce protective and durable immunity. Clarify the structural mechanism for specific neutralizing antibody would help understand failure neutralization caused by virus mutation, as well as provide essential information for advancing antibody design.

IGHV3-53 gene is the most frequently used IGHV gene for targeting the RBD, and the crystal structures of several encoded antibodies, including CC12.1 as the best, were revealed recently [29] . In this work, we performed and analyzed the molecular dynamics CC12.1 forms additional binding with the distal motif while similar contact is absent for ACE2 bound with SARS-CoV-2, as well as for ACE2 bound with SARS-CoV RBD.

Analyzing of the trajectories of molecular dynamics simulations lasting for 200ns of binary complexes of SARS-CoV-2 RBD with CC12.1 and ACE2 indicates that, the superior of almost double fold area on binding surface maintains (Fig. 1B) . RMSD values of RBDs and receptor in different systems were calculated and plotted for the whole 200 ns simulation time, which reflected the stability of binary complexes ( Fig. 1C and Fig. S1 ).

CC12.1 bound RBD show the highest stability with the lowest RMSD values, followed by ACE2 bound RBD. To take an insight for conformation stabilizing of SARS-CoV-2 RBD, the distributions of residue flexibility in apo, ACE2 bound and CC12.1 bound form were investigated by calculation of RMSF values, respectively. The maximum change of RMSF values occurs in the region of residue numbers 473-488, which is consistent with the distal motif mentioned before (Fig. 1D) . Average RMSF value of the region reduced from 5.45 to 2.49 by ACE2 binding, and as low as 1.11 by CC12.1 binding. In the apo form or ACE2 bound form of SARS-CoV RBD, the corresponding region of distal motif also saw the maximum change of RMSF values (Fig. S2) . It is reported that SARS CoV-2 invades host cells via CD147 except for ACE2 [30] . The binding mode between human CD147 and SARS-CoV-2 RBD was predicted by docking and the binding region of CD147 is different from ACE2 and CC12.1 with small overlap (Fig. S3 ). The result indicates that it is possible for SARS-CoV-2 RBD to bind CC12.1 and CD147 both at the same time although CC12.1 may be only binding to SARS-CoV-2 RBD partially.

In summary, comparison of SARS-CoV-2 RBD with CC12.1 and ACE2 binding modes indicates significant larger interface formed with CC12.1 than ACE2. Consistent with the significant structural difference between SARS-CoV-2 and SARS-CoV RBDs in crystal structures [31] , the binding on the loop in the distal end of RBD, which was referred as the distal motif (residue numbers 473 to 488), was found as the most significant difference. It is reported that YQAGSTPCN (residue numbers 473 to 481) is one of the SARS-CoV-2 spike protein multi-epitopic regions which inspires us to focus on the distal motif next [16] . 

To better understand the contribution of the enhanced binding interface with the distal motif, sequence BLAST of SARS-CoV-2 RBD as well as human SARS-CoV RBD and some other bat SARS-like coronaviruses was conducted (Fig. S4) . It is notable that the motif barely shows any homology with only 4 out of 15 residues sharing conservation with any other coronaviruses that could bind the human ACE2 receptor [32] (Fig. 2A) . Thus, enhanced binding with this motif might be the important reason for failure of neutralization of previous SARS-CoV antibodies and the specificity of antibodies for SARS-CoV-2.

Considering the sequence differences of the motif among these coronaviruses, it could be speculated that the distal motif wasn't important for ACE2 binding. Furthermore, any mutations of the motif might weaken the binding affinity of current SARS-CoV-2 antibodies with few influences on the binding with receptor ACE2. The consequences will be explored and presented more sufficient in the following sections. Five out of six CDRs of CC12.1 antibody are involved in the binding with RBD (Fig. 2B ). For SARS-CoV-2 RBD, residues including Arg403, Lys417, Phe456, Arg457, Tyr473, Ala475, Ser477 and Glu493 were involved and exhibited important roles since these residues mutated in SARS-CoV ( Fig. 2A ). Computation and mapping of the electrostatic potential of the contact interface indicate obvious complementarity for the corresponding contact area (Fig. 2C ).

The protruding negative electrostatic potential surface formed by the distal motif enables itself embedded in the positive electrostatic groove formed by CDR H1 of CC12.1. Both contact areas of CC12.1 and ACE2 bind with SARS-CoV-2 RBD are almost the same.

However, the distal motif is exposed when ACE2 bound with. It could be assumed that the electrostatic complementary drives the initiate binding of the RBD with CC12.1. 

In apo protein of SARS-CoV-2 RBD, disulfide bond formed between Cys480 and Cys488 helps to stabilize the distal motif loop [23] . The disulfide bond also remains stable with Table S1 ). Each of the three residues, Y473, A475 and N487, could form stable hydrogen-bonding interaction with antibody which was located near Cys480 and Cys488. With the stable disulfide bond formed between Cys480 and Cys488, the three hydrogen bonds provide forces of different orientations to stabilize the binding complex.

As for the distal motif with ACE2 bound, only stable disulfide bond couldn't avoid the flexible conformation change. The hydrogen-bonding network stabilizes the conformation of distal motif to a great extent.

It is notable that eight residues in distal motif have been found mutated in SARS-CoV-2 genomes from 3333 samples of the GISAID database [33] . The most frequently mutated residue in distal motif is S477, which is first sampled since Jun, 2020. (Fig. S5 ).

Sporadic samples have been observed for the other seven mutations, mostly after July, 2020. One out of 3333 genomes has the Y473 or T478 or N481 or G482 mutated, four genomes have the V483 mutated, five genomes have the F486 mutated and eight genomes have the E484 mutated. Despite the fact that only sporadic mutations have been found for these residues, the potential impact of these mutations should not be ignored considering the huge and increasing infected population. 

Extensive hydrogen bonds were found between RBD and heavy chain of CDRs. RBD forms four hydrogen bonds with CDR H1, including L455-V H Y33, Y473-V H S31, A475-V H N32, S477-V H G26 (Fig. 4A) S56-D420 was also reported in the previous study [29] (Fig. 4B) . At CDR H3, Stable hydrogen-bonding interactions were observed for Y453-V H D97 and N487-V H R94 with 96.11% and 99.79% occurrence, respectively. Another hydrogen bond with lower occurrence of 60.76% between Q493 and V H Y99 was also observed. K417 forms a salt bridge with V H D97 with the occurrence as high as 73.69% (Fig. 4A and Table S1 ). In addition, hydrophobic interactions formed between V H L96 of CC12.1 and F456, Y489 of the RBD were also found to be helpful for efficient binding. Considering the stable hydrogen bonding networks, SNY and SGGS are identified as two motifs that are crucial for antibody binding. The residues in SARS-CoV-2 RBD that interact with SNY and SGGS motifs are predicted as T-cell and B-cell epitopes [34] . Some of these residues, such as D420 and N487, are responsible for antibody-escape mutations which implicates the importance of these two motifs for efficient antibody binding [35] . In view of the conservation of two motifs among other IGHV3-53 encoded antibodies [29] , it could be assumed that these two motifs might also be critical for other IGHV3-53 encoded antibodies binding with the SARS-CoV-2 RBD. Table 1 . Computed relative binding free energy after point mutation in the SARS-CoV-2 RBD-CC12.1 antibody complex.

Similar interactions between SARS-CoV-2 RBD and ACE2 were investigated to explore the potential mutations for advanced antibody design. Interactions at the same region of RBD for ACE2 bound were found to be much weaker or even absent ( Fig. 4A and C). Few hydrogen bonds and salt bridges were found with ACE2 bound. However, two hydrogen bonds formed by G476 (RBD) and Q24 (ACE2), Q493 (RBD) and K31 (ACE2) 

Compared to heavy chain of antibody, fewer hydrogen bonds were found with light chain.

All efficient hydrogen bonds were formed with CDR L1 and L3. At CDR L1, V L G28 and G502, V L Y32 and G496 form hydrogen bonds with occurrence of 99.78% and 84.06%, respectively ( Fig. 5A and Table S1 ). V L S30 could form hydrogen bond with N501, G496 or Q498 alternatively with total occurrence of 73.63%. At CDR L3, side chain of V L S93 turns over from outward to inward to RBD gradually along with the simulation and maintains a stable hydrogen bond with D405 after 70 ns ( Fig. 5A and B) , despite the distance between the corresponding acceptor and donor heavy atoms of hydrogen bond is 8.07 Å in crystal structure. Considering that V L S93 is also conserved in some IGHV3-53 encoded antibodies [29] , V L S93 may also be another important residue in CDR L for this type of antibodies. Another two efficient hydrogen bonds were found on Y505 with V L Q90 and V L L91 at the same time with 86.61% and 99.74% occurrence, respectively ( Fig.   5A and Table S1 ). R403 and V L N92 form another hydrogen bond and maintain 86.80% of simulation time. In addition, V L K97 forms an unstable salt bridge with E406 with only 23.02% occurrence and a very stable hydrophobic center was also found among V L I2, V L I29 of CC12.1 and Y505 of RBD.

With ACE2 bound, none of interactions were found on R403, D405, G496 and N501 of RBD ( Fig. 5A Corresponding residues of CC12.1 with potential interaction with T500 of RBD were examined to obtain similar efficient interaction. The lowest distance of 4.61 Å was measured between T500 and V L G68 heavy atoms in crystal structure which is far beyond the effective range to form a stable interaction. Mutation from V L G68 to D not only provides hydrogen acceptor atoms but also shortens the distance into the effective range.

After the 5 ns simulation of mutated complex which was quite stable (Fig. S7A) , the binding free energy was calculated. The OG1 atom of T500 forms a hydrogen bond with OD1/OD2 atom of V L D68 (mutated) alternatively during the whole 5 ns simulation, which means the V L G68→D mutation is helpful in forming efficient interaction with T500 of RBD. Reduction of -4.09 ± 1.19 kcal/mol (Table 1 ) of the binding free energy indicates the increase of the binding affinity as expected. CC12.1 with V L G68D mutation was also docked on SARS-CoV-2 RBD (Fig. S8B) . The interactions formed between G502/Y505 and mutated CC12.1 were the same as the wild type. As we expected, the OG1 atom of T500 forms a hydrogen bond with OD1 atom of V L D68.

Overall, these residues, D405, G502 and Y505, which involved in interactions with high occurrence with CC12.1, were identified as key epitopes. The mutation from V L G68

to D was proposed as a strategy for improving the antibody efficiency. It is noticeable that RBD may be not the only region where the immune-dominant epitopes located in [34, 39] .

The immuno-dominant epitopes for T-cell and B-cell have been predicted by various immunoinformatics methods, and other predicted immune-dominant epitopes in spike glycoprotein of SARS-CoV-2 indicate potential protective antibodies sites [40] . 

To understand the reason for why CC12.1 could bind with SARS-CoV-2 specifically but not with SARS-CoV, we carried out MD simulation with SARS-CoV RBD-ACE2 complex (PDB ID: 2AJF) (Fig. 6A ). In the following text, we use SARS-CoV-2 sequence number to compare with the corresponding number for SARS-CoV with a subscript "S1."

Conserved interactions were found for SARS-CoV and SARS-CoV-2 due to the high similarity of sequences, including hydrogen bonds formed by Y436 S1 -D30, N479 S1 -K31, Y491 S1 -E37, N473 S1 -Y83, G488 S1 -K353 and T486 S1 -D355. The occurrence of the last two hydrogen bonds achieved as high as 98.73% and 90.58%, respectively ( Fig. 6B and C, Table S2 ). Besides, hydrophobic contacts still form among L472 S1 , L79 and M82, although F486 of SARS-CoV-2 RBD mutates to L472 S1 in SARS-CoV. Special attention has been paid on those crucial residues for SARS-CoV-2 antibody/ACE2 binding but not dedicated to efficient SARS-CoV ACE2 binding. Due to the K417→V404 S1 mutation, D30 of ACE2 forms a fluctuant hydrogen bond with Y442 for only 32.61% of simulation in SARS-CoV RBD-ACE2 complex instead of forming the salt bridge with K417 of SARS-CoV-2 RBD.

Previous study reported the importance of V404 S1 →K417 mutation for enhancing the ACE2 binding of SARS-CoV-2 RBD [25] . To evaluate the impact of this mutation on antibody binding to SARS-CoV-2 RBD, single mutation from K417 to V has been established and results in obvious perturbation to binding affinity by increasing binding free energy of 7.41 ± 0.94 kcal/mol (Table 1 ). In addition, some escape mutations locate in the distal motif and cause the neutralization failure of some mAbs that share the same recognition region with CC12.1 [41] . Since residues on distal motif contribute specific interaction in SARS-CoV-2 RBD-antibody complex and the limited conversation of the distal motif region, further single mutations were also implemented. The Y473→F460 S1 mutation may directly lead to the break of Y473-V H S31 interaction because of the phenolic hydroxyl group deletion. The A475→P462 S1 displacement may cause conformation change against with CC12.1 binding, due to the increased rigidity caused by Pro residue [25] . S477 was found to be the most frequent mutated residue on distal motif. Thus, these three residue mutations were simulated for binding free energy calculation (Fig. S7B) .

Results show increasing energy value of 1.06 ± 1.09 kcal/mol and 5.26 ± 0.99 kcal/mol for Y473→F460 S1 and A475→P462 S1 , respectively. However, S477→G464 mutation increases binding affinity by -2.92 ± 0.98 kcal/mol, perhaps due to the reduction of electrostatic repulsion with V L G26 of CC12.1. Finally, K417, Y473 and A475 were identified as key residues dedicating to binding specificity of SARS-CoV-2 antibody. Our results show that mutations of several key residues may cause the loss of antibody cross-neutralization between SARS-CoV-2 and SARS-CoV, which may explain why only limited cross-neutralization activity was found in convalescent sera obtained from SARS-CoV and SARS-CoV-2 patients [15] . Several reinfection cases have been reported and the whole genome analysis shows the differences between the SARS-CoV-2 strains from the first and second episode [42] [43] [44] . This indicates that none of only one type of antibody would perfectly protect people from infection. To resist the potential mutational escape of different SARS-CoV-2 strains, the antibody cocktail therapy could be used [45, 46] . 

Neutralization towards to the severe acute respiratory syndrome coronavirus 2 (SARS- with key epitopes efficiently were identified. By forming extensive and stable hydrogenbonding networks, enhanced binding competitivity of antibody has been achieved compared to receptor ACE2. Two single site mutations, V H V98E and V L G68D in antibody are proposed to imitate the interactions between SARS-CoV-2 RBD and the receptor. These two single site mutations could enhance antibody binding which was validated by relative free energies calculation and molecular docking. Three residues, K417, Y473 and A475 are found crucial for specific binding of SARS-CoV-2 rather than SARS-CoV by antibody. Our study illustrates essential information for not only efficiency but also specificity of SARS-CoV-2 antibody on structural basis to promote advanced antibody design.

Crystal structures of three complexes, PDB ID: 6XC2, which includes SARS-CoV-2 RBD and CC12.1 antibody [29] ; PDB ID: 6M17, which includes the SARS-CoV-2 RBD and the human ACE2 [38] ; PDB ID: 2AJF [21] , which includes the SARS-CoV RBD and the human ACE2, were visualized and generated surface views using PyMOL program [47] .

The hydrogen atoms were added by PDB2PQR webserver [48] , and the electrostatic potentials were calculated using Adaptive Poisson-Boltzmann Solver (APBS) [49] in PyMOL. Multiple sequence alignment were created using Clustal W [50] , and the results were mapped using ESPript webserver [51] . GenBank accession numbers are: 

The crystal structures of complexes between SARS-CoV-2 RBD and CC12.1 antibody (PDB ID: 6XC2) and complexes between the RBD and human ACE2 (PDB ID: 6M17 and PDB ID: 2AJF) were used as the starting structure for MD simulations. Apo protein of SARS-CoV-2 RBD was extracted from the crystal structure of PDB ID: 6M17. The protonation states of proteins were investigated and modified using the H++ webserver [52] . All proteins were applied with Amber ff14SB force field for the protein [53, 54] and solvated in a rectangular box of TIP3P water [55] , with a minimum distance between the protein and the box edge of 8 Å. The solvated protein was subsequently neutralized with Na + ion or Clion. Optimization and equilibration were applied to all systems before running production MD simulation. Initial optimization of the solvent consisted of 1000 cycles of energy minimization was followed by 50 ps of MD simulation at 298K (applying a positional restraint of 10 kcal mol −1 Å −2 on all solute atoms). The whole system was then optimized by 1000 cycles of energy minimization with a restraint on the protein Cα atoms (2.0 mol −1 Å −2 ). To prepare for production simulations, first, the temperature was increased from 50 to 298 K over a period of 10 ps (maintaining the mild restraint on Cα atoms).

Second, 50 ps simulation in the NPT ensemble at 298 K and a pressure of 1 bar was performed, again maintaining the mild restraint on Cα atoms. Thereafter, the whole system was briefly further equilibrated by 100 ps of NPT MD simulation (298 K, 1 bar). After this equilibration procedure, 200 ns MD simulation in the NPT ensemble at 298 K and 1 bar was carried out. Throughout, periodic boundary conditions were applied and the SHAKE algorithm was applied to fix all bond lengths involving hydrogen atoms. A time step of 2 fs was used, with a direct-space cut off radius of 8.0 Å for non-bonded interactions and particle mesh Ewald for long-range electrostatic interactions. The trajectory was sampled every 1 ps (500 steps intervals) for analysis. All simulations were performed using AMBER18 program [53] .

The AmberTools programs cpptraj [56] and MMGBSA [57] were used for analyzing trajectories. Structures were visualized using VMD [58] . The RMSD and RMSF values of the systems were calculated after imaging on the structure of the 200 ns trajectory.

Distances of hydrogen-bonding (distance cut-off of 3.50 Å), salt bridge (distance cut-off of 4.00 Å) and hydrophobic interaction (distance cut-off of 4.60 Å) were computed using WORDOM [59] , and mapped as heat map using GNUPLOT [60] . The information of SARS-CoV-2 genomic epidemiology was obtained from GISAID database [33] . To calculate the relative binding free energies (ΔΔG) caused by residue mutations, residue name was changed manually in crystal structure (PDB ID: 6XC2) and side chain deleted previously was modified using tleap. Exactly the same optimization and equilibration protocols were used for MD simulations of the modified crystal structures. In the following, production simulation of 5 ns was performed. MMGBSA was used to calculate the binding free energies of mutated complexes, and the calculated results were compared with the binding energy of the first 5 ns simulation of SARS-CoV-2 RBD-CC12.1 complex (PDB ID: 6XC2) to get the relative free energies of binding ΔΔG.

All the docking experiments were conducted by HDOCK webserver [61, 62] . Crystal structures of human CD147 and SARS-CoV-2 RBD were obtained from PDB ID: 3B5H, chain B and PDB ID: 6M17, chain E respectively. The mutated CC12.1 structure that used for docking was extracted from the first frame of 5 ns production simulation to avoid the potential conformation bump. The crystal structures of SARS-CoV-2 RBD that used for docking on mutated CC12.1 was obtain form PDB ID: 6XC2, chain Z.

Finally, all the materials and methods we used were shown as a workflow (Fig. S9 ).

A new coronavirus associated with human respiratory disease in China

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

World Health Organization (2021) Weekly operational update on COVID-19 -22

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Repurposed Antiviral Drugs for COVID-19 -Interim WHO Solidarity Trial Results

The trinity of COVID-19: immunity, inflammation and intervention

SARS-CoV-2 Vaccines: Status Report

Developing COVID-19 Vaccines at Pandemic Speed

Learning from the past: development of safe and effective COVID-19 vaccines

COVID-19: Coronavirus Vaccine Development Updates

Safety and efficacy of the mAb nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and interactions

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

2021) mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

SARS-CoV-2 evolution during treatment of chronic infection

Structural basis of a shared antibody response to SARS-CoV-2

CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Structural basis of receptor recognition by SARS-CoV-2

Discovery of a rich gene pool of bat SARSrelated coronaviruses provides new insights into the origin of SARS coronavirus

Data, disease and diplomacy: GISAID's innovative contribution to global health

Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Frenkel-Morgenstern M (2020) Immunoinformatics and Structural Analysis for Identification of Immunodominant Epitopes in SARS-CoV-2 as Potential Vaccine Targets

The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. Brief Bioinform

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing

Genomic evidence for reinfection with SARS-CoV-2: a case study

Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

The PyMOL Molecular Graphics System

PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations

Electrostatics of nanosystems: Application to microtubules and the ribosome

Clustal W and clustal X version 2.0

Deciphering key features in protein structures with the new ENDscript server

H++3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations

An overview of the Amber biomolecular simulation package

Comparison of Simple Potential Functions for Simulating Liquid Water

PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data

MMPBSA.py: An Efficient Program for End-State Free Energy Calculations

VMD: Visual molecular dynamics

Wordom: a program for efficient analysis of molecular dynamics simulations

0: A portable interactive plotting utility

HDOCK: a web server for protein-protein and protein-DNA/RNA docking based on a hybrid strategy

The HDOCK server for integrated protein-protein docking

Yushu Ge: Conceptualization, Validation, Formal analysis, Writing -Review & Editing. Bin Zhong: Formal analysis, Investigation

We gratefully acknowledge the financial support from Major Research Plan of the National 

The authors have no conflict of interest.